Pharmaceutical giants are restructuring research and development portfolios to capitalize on the rapid expansion of the GLP-1 market. The drug class, initially developed for type 2 diabetes management, has demonstrated significant efficacy in obesity and cardiovascular risk reduction.
Pipeline Consolidation
Capital is moving away from early-stage oncology and rare disease programs toward next-generation oral formulations and combination therapies. Global health systems are evaluating cost-benefit dynamics as long-term prescription demand surges.